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Abstract
Background: Meperidine (pethidine) is an opioid analgesic that offers little advantage relative to other opioids
and several disadvantages including limited potency, short duration of action, and the production of a neurotoxic
metabolite (normeperidine) with a long half-life. Older adults are more sensitive to meperidine’s side effects and
may have diminished renal function which leads to the accumulation of normeperidine. The Institute for Safe
Medication Practices has suggested avoiding meperidine in older adults, limiting its dose (≤600 mg/day) and
duration of use (≤48 h). The objective of this study was to determine the level of meperidine use in older adults
and assess the dosage and duration of meperidine with reference to these safety recommendations.
Methods: A longitudinal study using administrative healthcare data was conducted to examine meperidine
utilization and levels of high dose and extended duration prescribing among persons ≥65 years of age between
April 1, 2001, and March 31, 2014 in Manitoba, Canada. The number of meperidine prescriptions, users, duration of
treatment, defined daily doses (DDD) dispensed and number of prescribers were determined over the study period.
Results: In the Manitoba older adult population there was a marked decline in meperidine users and prescriptions
from 2001 to 2014. There was an average use of 26.4 (95 % CI 24.0–28.8) DDDs of meperidine per user per year.
While only 3.7 % of the prescriptions exceeded the 600 mg maximum daily dose, 96.7 % of prescriptions exceeded
the recommended 2 days of therapy. For the remaining users of meperidine, the amount of meperidine used per
person rose from 18.98 to 56.14 DDDs/user/year over the study period. The number of prescribers of meperidine
declined throughout the study, but low DDD prescribers declined more quickly than high DDD prescribers.
Conclusions: While meperidine use has declined, the remaining use appears to be decreasing in safety, with more
meperidine prescribed per user. This seems to be driven by the continued prescribing by a small number of high DDD
prescribers. Targeted educational initiatives directed at this small group of prescribers may be helpful. Alternatively
removing meperidine from medication insurance schemes may provide additional incentive to avoid meperidine in
older adults.
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Background
Meperidine (pethidine) was once one of the most com-
monly used opioid analgesics in North America [1]. More
than 50 years after its introduction the American Pain
Society began pointing out the problems with meperidine
and suggesting limiting its use [2]. Meperidine has a rapid
onset of action which makes it more prone to abuse than
other opioids [3–5]. In terms of efficacy, meperidine lacks
potency and has a relatively short duration of action (2.5
to 3.5 h) compared to morphine [6]. As such, it is fre-
quently under-dosed and given at intervals longer than its
duration of action resulting in poor pain control [7]. While
meperidine has a half-life of only 2 to5 h, its metabolism
produces normeperidine, a neurotoxic metabolite with a
much longer half-life of 15 to 30 h [6]. This creates a clin-
ical dilemma where the dosing frequency necessary for
adequate pain control is likely to produce accumulation of
normeperidine which has been associated with delirium
and seizures.
There are a number of reasons why older adults may
experience more adverse effects related to meperidine.
Firstly, older adults are more sensitive to the central ner-
vous system side effects of meperidine including anxiety,
hallucinations, confusion, and seizures [6, 8]. Secondly,
renal function generally diminishes with age, and as nor-
meperidine is eliminated renally, older adults are more
likely to accumulate normeperidine with repeated dosing,
putting them at elevated risk of toxicity. It is therefore not
surprising that meperidine has been included on the Beers
list of medications that are best avoided in older adults [9,
10]. A recent examination of the outcomes associated with
medications on the Beers list prescribed to older adults
found meperidine to be the medication most strongly
associated with unplanned hospitalizations (OR 2.37, 95 %
CI 1.25–4.50) [11].
There has been further action to limit the use of meperi-
dine. In Canada, the Institute for Safe Medication Practices
(ISMP) issued safety warnings in 2004 and 2005, recom-
mending that meperidine be limited to situations where
alternative opioids are contraindicated [12, 13]. When its
use cannot be avoided the ISMP recommendations suggest
that doses should not exceed 600 mg of meperidine in
24 h, and duration of use should be limited to 48 h.
Given the higher risk in older adults we examined the
use of meperidine in people 65 years of age and older in a
longitudinal utilization analysis in Manitoba, Canada. The
objective of this study was to determine the level of
meperidine use in older adults and assess the dosage
and duration of meperidine with reference to these
safety recommendations.
Methods
A longitudinal study using administrative healthcare data
was conducted to examine meperidine utilization among
persons 65 years of age and older between April 1, 2001
and March 31, 2014 in the province of Manitoba, Canada.
Prescription data were obtained from the Manitoba Drug
Program Information Network (DPIN) database through
the Manitoba Centre for Health Policy (MCHP) at the
University of Manitoba. DPIN is a centralized system used
to process all outpatient prescriptions in Manitoba. This
linked data provides relatively complete population data
for Manitoba’s 1.3 million people and is routinely used in
administrative database studies [14–16].
The number of oral meperidine prescriptions, users,
days of treatment as prescribed, and defined daily doses
(DDD) dispensed were determined. In Canada oral me-
peridine is only available as a 50 mg tablet. The World
Health Organization DDD represents the assumed average
maintenance dose for a drug used for its main indication
in adults. The DDD value for meperidine is 400 mg which
is equivalent to 50 mg given every 3 h [17].
Results were summarized across the overall study
period, and were examined within each fiscal year (April
1st to March 31st). Prescriptions and users rates were
presented per 1000 persons based on Manitoba Health
Registry data. Results were also stratified into age groups
(65–74, 75–84, and ≥85 years) based on the age at the
time of dispensation. The daily dose was calculated using
prescription quantity multiplied by strength and divided by
the duration of prescription. All pharmacists are required
to enter the estimated days supply based on the prescrip-
tion’s quantity and directions. The duration of prescription
was taken as the lesser of the days supply field as entered
by the dispensing pharmacist, or the number of days to
when the next prescription was filled. Prescriptions were
classified as high dose if they exceeded 600 mg per day.
Users were classified as high dose users overall if they had
one or more high dose prescriptions.
Prescriptions were considered to exceed the duration
safety recommendation if the duration was more than
2 days. However, since the days supply field may not be
accurately entered by the dispensing pharmacists, the
prescription duration was also assessed by converting pre-
scription quantities into DDDs. Prescriptions that exceeded
2 DDDs were considered to have exceeded the safety rec-
ommendation to limit use to 2 days of therapy.
The prescribers of meperidine were also studied. A cu-
mulative frequency distribution of meperidine prescribers
was created to determine the number of prescribers
responsible for 50 % of meperidine prescribing. The
proportion of prescribers prescribing larger quantities
of meperidine was also examined on an annual basis.
Where greater than 50 % of an individual prescriber’s
prescriptions were for more than 6 DDDs, prescribers
were classified as high DDD prescribers. Six DDDs rep-
resents a prescription quantity of 2400 mg or twice the
ISMP recommended maximum (600 mg/day for 2 days).
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Prescribers who fell below this threshold were classified
as low DDD prescribers.
Data analysis was done using SAS 9.4® (SAS Institute
Inc., Cary, NC, USA). Univariate and least squares regres-
sion analysis were used to describe and analyze our data.
For age-stratified data, ANOVA was used to compare an-
nual rates between age groups with the Tukey method used
to make pairwise comparison where the ANOVA showed a
significant overall difference between the groups.
Approval for this study was obtained from the University
of Manitoba’s Health Research Ethics Board and Manitoba
Health’s Health Information Privacy Committee. These
committees do not require individual consent for research
conducted using de-identified administrative data when
reasonable safeguards to protect confidentiality and security
of personal health information are in place.
Results
We identified 9196 prescriptions for meperidine dispensed
between April 1st, 2001 and March 31st, 2014 for 1990
persons aged 65 years and older in the DPIN database. In
this overall population, there were 1.47 (95 % Confidence
Interval (CI) 0.60–2.47) users per 1000 persons per year
with 3.82 (95 % CI 3.27–4.38) prescriptions per 1000 per-
sons per year. There was a marked decline in meperidine
usage over the study period (Fig. 1).
The majority of meperidine users were female (1210;
60.8 %). When their first meperidine prescription was filled
most users were 65 to 74 years (1160; 58.3 %) with a
smaller number of users in the 75–84 (633; 31.8 %) and
≥85 (197; 9.9 %) age groups. The DDDs of meperidine
dispensed declined with increasing age. The 65–74 age
group had a mean rate of 50.2 (95 % CI 44.4–56.0), with
26.9 (95 % CI 22.2–31.5) for the 75–84 age group, and 17.8
(95 % CI 11.5–24.1) DDDs/1000-person-years in the 85
plus age group. Annual rates were found to be different
between age groups (F (2, 36) = 42.23; p < 0.0001), and pair-
wise comparisons showed significant differences between
all age groups.
At the level of the user, the mean number of prescrip-
tions per user per year was found to be 3.0 (95 % CI
2.8–3.2) prescriptions per year, representing 26.4 (95 %
CI 24.0–28.8) DDDs per user per year. The mean overall
daily dose of meperidine per prescription was 249.9 mg/
day (95 % CI 242.3–257.4), and a mean prescription
quantity of 8.80 DDDs/prescription (95 % CI 8.62–8.99).
When considering the prescribed dose of meperidine,
127 (6.4 %) of the users received at least one meperidine
prescription above the maximum recommended dose of
600 mg per day. Overall, 336 (3.7 %) of the meperidine
prescriptions exceeded the 600 mg maximum daily dose.
However, when considering the duration of treatment,
prescription durations greatly exceeded the maximum
48 h recommended, with a mean length of 20.9 days
(95 % CI 20.5–21.0). Overall, 96.7 % (8896) of prescrip-
tions exceeded 2 days, and 54.3 % (4994) exceeded
2 weeks duration (Fig. 2). In terms of DDD standardized
days of treatment, 88.9 % (8178) of all prescriptions
dispensed were for quantities exceeding 2 DDDs, and
43.6 % (4005) of all prescriptions were for the equivalent
of more than a week of therapy (≥8 DDDs) (Fig. 3).
Between 2001 and 2013, the rate of meperidine use in
this population declined steadily (Fig. 1). However, when
the remaining users of meperidine were considered, the
amount of meperidine per user was increasing (Fig. 4). Lin-
ear regression analysis of this data suggests a significant
Fig. 1 Meperidine utilization over time
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trend to increased intensity of use per individual user
(Fig. 4). The mean number of prescriptions per user rose
from 2.42 prescriptions/user/year in 2001/2002 to 5.15
prescriptions/user/year in 2013/2014 (F (1, 11) = 73.81,
p < 0.0001; R2 = 0.87). The amount of meperidine,
expressed in DDDs/user/year, also rose steadily, from
18.98 in 2001/2002, to 56.14 DDDs/user/year in 2013/
2014 (F (1, 11) = 38.42, p = 0.0001; R
2 = 0.78). Additionally,
the mean number of DDDs per prescription increased
from 7.84 DDD/prescription to 10.90 from 2001 to 2013
(peaking in 2011 at 13.47) (F (1, 11) = 16.25, p = 0.002).
Less than 5 % (37/743) of the prescribers were respon-
sible for over 50 % of all meperidine prescriptions (4612
out of 9196 prescriptions). This high prescribing group
(the top 5 % of prescribers) wrote an average of 125
prescriptions per prescriber in contrast to the remaining
prescribers (i.e. the remaining 95 % of meperidine pre-
scribers) who averaged just 6.5 prescriptions per prescriber.
The number of prescribers of meperidine declined dra-
matically from 247 prescribers to 96 prescribers by the end
of the study (Fig. 5). The number of low DDD prescribers
declined more, from 137 to 32 prescribers, than high DDD
prescribers group which fell from 110 to 64 prescribers. As
a result, the proportion of high DDD prescribers has risen
steadily across the study period from 44.5 % in 2001/02 to
66.7 % in 2013/14.
Discussion
At a population level, there has been a marked decline in









































Fig. 3 Distribution of DDDs per prescription
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(Fig. 1). This is reassuring given that a key message of the
safety warnings was to avoid meperidine in older adults.
Unfortunately the nature of the remaining small amount of
use is concerning. While only a small percentage (3.65 %)
of prescriptions exceeded the recommended dosing limit of
600 mg per day, the duration of prescriptions almost uni-
versally exceeded the recommended limit of 48 h (96.7 % of
prescriptions). Overall the average DDDs per prescription
(8.80) is the equivalent of just over seventy 50 mg tablets.
The number of prescriptions and DDDs per user increased
over the study period (Fig. 4), indicating an increasing level
of presumably inappropriate use.
Many utilization studies have considered meperidine
use in the hospital setting [7, 18–20] with a smaller
number of studies considering the overall population use
in the community [21, 22]. To the best of our know-
ledge, this is the first study to consider population level
data exclusively in the higher risk older adult population.
Fischer et al conducted a review of opioid analgesic use
in Canada from 2005 to 2010 by extrapolating the data





















Fig. 5 Meperidine prescribers
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from a representative sample of retail pharmacy prescrib-
ing records [22]. They found that Canadian average use of
meperidine fell from 60 to 43 DDD/1000 persons per year
over their study period. Manitoba had among the lowest
levels of use in Canada with use falling from 34 to 30
DDD /1000 population per year. These values correspond
reasonably well to our previous assessment of meperidine
use in the overall population with use falling from 46 to
31 DDD/1000 persons per year from 2001 to 2010 [23]. In
this study, meperidine use in the population 65 years of
age and older at 26.4 DDD/1000 persons per year was
considerably lower than values previously reported for the
overall population.
This low and declining level of population use has been
previously shown in Nova Scotia, Canada [21]. That study
found that only 30 (2.4 %) prescribers in the province were
responsible for 40 % of the meperidine prescribed. A very
similar concentration of meperidine prescribing was found
in this study (5 % prescribers were responsible for 50 % of
prescribing). Previous study in Manitoba has also shown
that the number of prescribers of meperidine has been
falling with less than 4 % of eligible prescribers prescribing
meperidine to the broader population [23]. This is also
evident in the absolute decline in the number of meperi-
dine prescribers in Manitoba (Fig. 5). The higher decline
in low DDD prescribers relative to high DDD prescribers
may provide an explanation for the paradoxical rise in
DDDs and prescriptions per user/year (Fig. 4). Prescribers
who are sensitive to safety warnings may use lower quan-
tities, and ultimately elect to discontinue use of meperi-
dine in older adults. Prescribers who have ignored the
safety warnings may tend to prescribe higher DDDs and
continue to not only prescribe meperidine but to prescribe
meperidine in large amounts. In an attempt to target this
small resistant group, direct education and feedback to
these prescribers has been shown to have some impact in
reducing meperidine use [21].
There are some limitations to this study. The data avail-
able is limited to prescription filling records from commu-
nity pharmacies. No information on meperidine use in
hospital is available. However, given that many hospitals
have removed meperidine from their formularies and taken
efforts to restrict its use, hospital-based meperidine use is
expected to be limited [19, 20]. The DPIN records provide
only records of filling a prescription and do not assess if the
medication was actually taken. This is a common limitation
of utilization studies that make use of administrative data
[24, 25]. The days supply field in the prescription records is
manually entered by pharmacists and may not always be a
reliable estimate of prescription duration. This limitation
was addressed by also estimating the prescription duration
based on the quantity of medication dispensed and its
equivalent as DDDs. Safety warnings allow that meperidine
use may be permissible for limited durations when patients
have an allergy to all other available opioids. It is expected
that this circumstance would be rare, but our records did
not provide allergy information.
Conclusions
Safety warnings and increased clinical awareness of the
problems with meperidine in older adults have resulted in
dramatic declines in the prescribing of meperidine to those
who are 65 year of age or older. However, the small amount
of remaining use appears to be less safe with an increase in
the DDDs per user per year. This appears to be primarily
related to a small number of high DDD prescribers that
have not responded to past safety warnings. Educational
initiatives directed at the small group of prescribers may be
helpful [21]. Given that safer opioid alternatives exist for
the vast majority of these patients, another approach may
be to remove insurance coverage for meperidine for those
over the age of 65 [26]. This may provide a further incen-
tive to avoid meperidine in this sensitive population.
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